
The Gates of the Alexandria Lighthouse Emerge From the Sea!
An extraordinary lifting operation
Thirty years after archaeologist Jean-Yves Empereur of the Centre d'Études Alexandrines (CEAlex) discovered the underwater remains of the Alexandria Lighthouse—one of the Seven Wonders of the World—in 1995, a new remarkable mission is underway.
Under the scientific supervision of archaeologist and architect Isabelle Hairy from the CNRS, the team has successfully lifted 22 of the lighthouse's largest stone blocks out of the water. These include monumental door lintels and jambs weighing 70 to 80 tons, the threshold, large base slabs, and parts of a previously unknown monument: a pylon with an Egyptian-style door crafted from the Hellenistic period.
The goal of this exceptional and spectacular operation is to study and scan these architectural elements, adding them to a collection of over 100 blocks already digitized underwater over the past decade. After photogrammetric processing, the scanned blocks will be handed over to volunteer engineers with La Fondation Dassault Systèmes. Like pieces of a giant archaeological puzzle, each block will be analyzed and repositioned virtually. Using scientific simulations and virtual worlds, the team of engineers will test hypotheses about the lighthouse's construction and collapse, creating a digital twin of this lost wonder. The virtual model will revive the lighthouse's original grandeur, allowing visitors to explore it as if they were on site.
A French-Led Excavation
The CNRS - specifically its permanent unit in Egypt, the Centre d'études Alexandrines - is conducting the lighthouse excavation under the authority of the Egyptian Ministry of Tourism and Antiquities. La Fondation Dassault Systèmes has supported the project for the last three years.
The 'PHAROS' Project
Funded by La Fondation Dassault Systèmes and led by Isabelle Hairy (CNRS - UMR 8167, Orient & Méditerranée), the PHAROS project brings together historians, numismatists, archaeologists, and architects to collect ancient depictions and descriptions of the lighthouse from the late fourth century BCE until its destruction in the early 15 th century CE. This research helps to fill gaps left by the highly fragmented archaeological remains, as the lighthouse was quarried for building materials after it ceased operation in 1303 until the construction of the Qaitbay Fortress in 1477.
These findings complement the parameters already available for the ongoing digital reconstruction, shedding light on the lighthouse's unique architecture—crucial since no major ancient lighthouse survives today. The Alexandria Lighthouse was the first of its kind and understanding its history offers insightful clues about how and why it collapsed.
About the Alexandria Lighthouse
Built at the beginning of the third century BCE by Ptolemy I, this incredible towering structure guided sailors approaching a treacherous coastline. Standing 100 meters tall, its beacon made the Egyptian city a shining hub at the heart of Mediterranean trade. Symbolizing the city's power and the prestige of its builders, Pharos can be regarded as humanity's first skyscraper. Its technical brilliance and architectural genius – emblems of the era's scientific and artistic peak – allowed it to withstand time and history for over 1,600 years.
A major documentary project
GEDEON Programmes, a renowned French producer of history and science documentaries, helped cofinance the 1995 Alexandria Lighthouse rescue mission and produced the acclaimed film 'The Seventh Wonder of the World' which was broadcasted on France 2 and major international channels such as the BBC, PBS, ZDF, RAI, NHK, and others. In 2025, GEDEON Programmes is again supporting the CEAlex's mission by funding the barge and crane used to lift the lighthouse blocks. This spectacular operation was filmed by GEDEON Programmes' teams, led by director Laurence Thiriat, for a 90-minute documentary set to premiere in prime time on France Télévisions.
About the Partners:
The Centre for Alexandrian Studies (CNRS/Ifao): Established in Alexandria since 1990, this CNRS research and support unit, under the direction of Thomas Faucher, focuses on the historical and archaeological study of the city of Alexandria and its surrounding countryside.
La Fondation Dassault Systèmes: The foundation places 3D virtual world technology at the service of education and scientific exploration. It supports the academic world, research centers, and public-interest organizations in their efforts to promote education, research, and heritage preservation. La Fondation Dassault Systèmes is also committed to inspiring careers in science and engineering, particularly among students. Going beyond mere financial support, La Fondation Dassault Systèmes, through its volunteers, provides cutting-edge technological expertise—a true driving force that helps its partners bring their projects to life and open up new horizons.
GEDEON Programmes: Specializing in historical, scientific, nature, and cultural documentaries, GEDEON Programmes has been a key player in French audiovisual production for over 30 years, with more than 50 films produced annually and distributed worldwide. Through its GEDEON Experiences division, the company also produces immersive exhibitions and virtual reality experiences on historical and cultural themes.
France Télévisions: France Télévisions is proud to support the documentary The Lighthouse of Alexandria, winner of the Global Doc call for projects—an alliance of 10 international public broadcasters dedicated to producing ambitious and innovative projects.
As a major player in the documentary field, France Télévisions highlights the great scientific adventures of our time. In Science Grand Format, a weekly program hosted by Mathieu Vidard, passionate scientists share their latest discoveries about the mysteries of science and great civilizations.
CNRS : A major player in fundamental research worldwide, the Centre national de la recherche scientifique (CNRS) is the only French organization active in all fields of science. Its unique position as a multi-specialist enables it to bring together the various scientific disciplines to shed light on and understand the challenges of today's world, in conjunction with public and socio-economic players. Together, the sciences are at the service of sustainable progress that benefits society as a whole.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
12 minutes ago
- Business Wire
Vistagen to Present at the BTIG Virtual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at


Business Wire
12 minutes ago
- Business Wire
ImmunoPrecise Releases New Findings Showing LENS ai ™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. The platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. 'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENS ai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.' Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed. LENS ai 's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods. Study Highlights 217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92. Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments. Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays. Read the full case study: [ link ] About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives. Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.


Business Wire
12 minutes ago
- Business Wire
Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference
BUSINESS WIRE)--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences. Scios 3 FIB-SEM offers high-powered versatility The Thermo Scientific™ Scios™ 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with automation to dramatically improve site-specific quality control. The Scios 3 FIB-SEM offers increased productivity for both industry and academia with enhanced lamella preparation, due to advances in FIB column performance. Ease-of-use upgrades will benefit microscopists of all experience levels. 'Researchers across the globe seek new and better materials for various applications – from clean energy and aerospace to productivity of digital devices,' said David Wall, vice president and general manager of materials science for Thermo Fisher. 'The current pace of the development of new materials and their increasing complexity poses significant challenges, and Scios 3 addresses those challenges head-on with world-class advancements designed to serve both academia and industry.' With advanced automation and high-throughput, Scios 3 improves ease of use, reliability and productivity. To learn more, stop by booth #1734 at M&M for a live demonstration or visit Talos 12 adapts to researchers across disciplines and experience levels Thermo Fisher has evolved the popular Talos transmission electron microscope (TEM) design, culminating in the Thermo Scientific Talos™ 12 TEM, making leading-edge sample analysis more accessible than ever for biological research, pathology and drug development. 'We're pleased to introduce Talos 12 at M&M this year to bring transmission electron microscopy to more researchers,' said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. 'A wide array of laboratories can now benefit from this adaptable 120kV instrument. Not only does the reduced footprint and next-generation enclosure fit into more lab spaces, but the streamlined workflows – from routine imaging of cells and tissues to AI-assisted sample characterization to cryo-EM – enable the user-friendly Talos 12 to support remote operation for collaboration regardless of location.' TEM systems often require highly skilled specialists, but Talos 12 lowers those requirements with new enhancements to improve ease of use while maintaining high quality imaging with high reproducibility. To learn more, stop by booth #1734 at M&M for a live demonstration or visit Stop by booth #1734 to see Scios, Talos and more Thermo Fisher will have a significant presence at the Salt Palace Convention Center. In addition to live demonstrations of Scios 3 and Talos 12, several other industry-leading solutions will be on full display. Stop by booth #1734 to engage with Thermo Fisher subject-matter experts as they discuss the latest advancements in microscopy innovation and analytical research technology. Additionally, Thermo Fisher has hosted a 'Women in Microscopy' breakfast at M&M for more than two decades and will continue that tradition at the Hyatt Regency on the morning of July 30. Dr. Amelia Dempere, Director of the Nanoscale Research Facility (NRF) at the University of Florida, will talk about her career journey and the ever-increasing importance of women in research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit